Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Biocept Inc (NQ: BIOC )

5.360 USD -0.120 (-2.19%)
Official Closing Price Updated: 7:57 PM EST, Jan 15, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 461,300
Open 5.540
Bid (Size) 5.310 (100)
Ask (Size) 5.330 (12)
Prev. Close 5.480
Today's Range 5.300 - 5.740
52wk Range 0.2100 - 6.350
Shares Outstanding 68,213,349
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Biocept to Present at H.C. Wainwright Virtual BioConnect Conference
CEO Michael Nall to participate in diagnostics and devices panel discussion hosted by former FDA Commissioner Dr. Scott Gottlieb 
From PR Newswire
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve... 
From PR Newswire

Performance

YTD
+13.08%
+13.08%
1 Month
+8.94%
+8.94%
3 Month
+14.53%
+14.53%
6 Month
+661.47%
+661.47%
1 Year
+1414.12%
+1414.12%

More News

Read More
Biocept Enters into Laboratory Services Agreements with Two Southern California Regional Independent Physician Associations
From PR Newswire
Biocept Provides Business Update
From PR Newswire
Biocept Issues Letter to Stockholders
From Business Wire News Releases
Biocept's Target Selector™ Liquid Biopsy Demonstrated High Accuracy When Used for Monitoring the Progression of Metastatic Breast Cancer in Study Conducted at Johns Hopkins Sidney Kimmel Cancer Center
From PR Newswire
While The U.S. Faces Insufficient COVID-19 Testing Volume, EIR Healthcare Launches MedModLabs to Expand Access Immediately
From PR Newswire
Study Shows Biocept's Assays are Viable and Sensitive for Detecting Tumor Cells and Biomarkers in the Cerebrospinal Fluid of Patients with Breast and Lung Cancer that has Metastasized to the Central N
From PR Newswire
Results from Study Using Biocept's Target Selector™ Testing to Monitor Breast Cancer Disease Progression to be Presented at 2020 SABCS®
From PR Newswire
Biocept Reports Third Quarter 2020 Financial Results
From PR Newswire
12 Healthcare Stocks Moving In Friday's Intraday Session
Tags NMTR ARPO SAVA
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.